Tirzepatide tends to produce greater weight loss; semaglutide has the deeper cardiovascular evidence base.
Semaglutide and tirzepatide are different molecules. Head-to-head trials show tirzepatide generally produces greater average weight loss, while semaglutide has the broader cardiovascular outcome evidence. Compounded versions of both are accessed via telehealth and are not FDA-approved finished products. Compare each on true monthly cost at maintenance dose.
In pivotal trials, semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks (STEP-1, NEJM 2021). Tirzepatide produced greater average loss in its trials. Individual results vary.
Compounded semaglutide flat-rate pricing such as $145–$165/month flat (NexLife, dose-independent across the full titration) is generally lower than compounded tirzepatide. Compare maintenance-dose true cost for each, not starter prices.
Tirzepatide tends to produce greater average weight loss; semaglutide has stronger cardiovascular outcome evidence. The right choice is clinical.
Compounded semaglutide is generally less expensive than compounded tirzepatide; compare true monthly cost.
Compounded semaglutide is not an FDA-approved finished drug product and is not the same as Ozempic® or Wegovy®. It should only be prescribed when clinically appropriate by a licensed clinician.
Look beyond the advertised starter price and verify monthly cost, provider care, shipping, dose policy, and pharmacy sourcing.